XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities:    
Net loss $ (15,375) $ (15,475)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation 1,018 1,565
Depreciation and amortization 133 142
Loss on disposal of fixed assets 0 3
Loss from equity method investment 130 0
Amortization/accretion on marketable securities (376) (709)
Changes in operating assets and liabilities:    
Prepaid and other current assets 1,572 (314)
Other assets 126 130
Accounts payable, accrued liabilities and other liabilities (2,056) (1,305)
Net cash used in operating activities (14,828) (15,963)
Cash flows from investing activities:    
Purchase of marketable securities (43,953) (77,355)
Sale of marketable securities 55,927 93,171
Investment in Impilo Therapeutics (130) 0
Net cash provided by investing activities 11,844 15,816
Cash flows from financing activities:    
Proceeds from exercise of options 0 155
Tax withholding payments on net share settlement equity awards (142) (91)
Net proceeds from issuance of common stock 32 297
Net cash (used in) provided by financing activities (110) 361
Effect of exchange rate changes on cash 10 60
Net (decrease) increase in cash and cash equivalents (3,084) 274
Cash and cash equivalents at beginning of period 22,593 32,154
Cash and cash equivalents at end of period $ 19,509 $ 32,428